Axsome NDA for AXS-12 in narcolepsy cataplexy accepted, FDA sets May 1, 2027 date

The FDA accepted Axsome Therapeutics' filing for AXS-12 (reboxetine) and said it does not currently plan an advisory committee meeting on the application.

41d ago